Myriad Genetics Secures Japan Approval for MyChoice® as Companion Diagnostic in Prostate Cancer

- Myriad Genetics Inc.,  a leader in molecular diagnostic testing and precision medicine,announced that Japan’s Ministry of Health, Labour and...

April 16, 2026 | Thursday | News
Telix Advances First Radiopharmaceutical Therapy Into Phase III For Glioblastoma Treatment

Telix Pharmaceuticals Limited announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivota...

April 16, 2026 | Thursday | News
PannTheraPi Advances PTI5803 into Phase 2a for Rare Epilepsy, Secures European Patent and Appoints New CSO

Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and sev...

April 15, 2026 | Wednesday | News
Renaissance Pharma Secures FDA Fast Track and IND Clearance for Daretabart in High-Risk Neuroblastoma

FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling ...

April 15, 2026 | Wednesday | News
Thermo Fisher Scientific Expands PPD™ Clinical Research Capabilities Through Strategic Data Collaboration with HealthVerity

Thermo Fisher Scientific, the world leader in serving science, announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD...

April 15, 2026 | Wednesday | News
EU Expands Dupixent Approval to Young Children with Chronic Spontaneous Urticaria

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy ...

April 14, 2026 | Tuesday | News
Roche Secures CE Mark for Elecsys NfL Blood Test, Expanding Access to MS Monitoring

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis...

April 14, 2026 | Tuesday | News
Neurocrine Advances Nxera-Discovered NBI-1117570 into Phase 2 for Schizophrenia

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development und...

April 14, 2026 | Tuesday | News
SynOx Therapeutics Reports Strong Phase 3 TANGENT Results With Emactuzumab In TGCT

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and...

April 14, 2026 | Tuesday | News
Redefining Drug Development: Integrating Science, Speed, and Strategy to Improve Success Rates

In this exclusive BioPharma Boardroom interaction, Thierry Van Nieuwenhove, CEO of Quotient Sciences, explores why nearly 90% of drug candidates fail and w...

April 14, 2026 | Tuesday | Interaction
Emergent BioSolutions Expands Access to NARCAN Nasal Spray with New Carrying Case, Multipacks, and Campus Outreach Initiative

  Emergent BioSolutions Inc. announced a series of initiatives designed to help increase access to NARCAN® Nasal Spray and encourage the pub...

April 09, 2026 | Thursday | News
Mesoblast Limited Secures U.S. Food and Drug Administration IND Clearance for Registrational Trial of Ryoncil in Duchenne Muscular Dystrophy

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the...

April 09, 2026 | Thursday | News
Sanofi’s Lunsekimig Delivers Strong Phase 2 Wins in Asthma and CRSwNP, Expanding Promise of Dual-Target Respiratory Therapy

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES pha...

April 08, 2026 | Wednesday | News
SonoNeu Emerges from Stealth to Advance Sonogenetics as a Breakthrough Drug-Free Therapeutic Modality

Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged&r...

April 08, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close